Format

Send to

Choose Destination
Nat Med. 2017 Aug 4;23(8):917-928. doi: 10.1038/nm.4381.

Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.

Author information

1
Medicines for Malaria Venture, Geneva, Switzerland.
2
Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York, USA.
3
Division of Infectious Diseases, Department of Medicine, Columbia University Medical Center, New York, New York, USA.

Abstract

The global adoption of artemisinin-based combination therapies (ACTs) in the early 2000s heralded a new era in effectively treating drug-resistant Plasmodium falciparum malaria. However, several Southeast Asian countries have now reported the emergence of parasites that have decreased susceptibility to artemisinin (ART) derivatives and ACT partner drugs, resulting in increasing rates of treatment failures. Here we review recent advances in understanding how antimalarials act and how resistance develops, and discuss new strategies for effectively combatting resistance, optimizing treatment and advancing the global campaign to eliminate malaria.

PMID:
28777791
PMCID:
PMC5747363
DOI:
10.1038/nm.4381
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center